Author Correction: Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase.

Autor: Baltgalvis KA; Vividion Therapeutics, San Diego, CA, USA., Lamb KN; Vividion Therapeutics, San Diego, CA, USA., Symons KT; Vividion Therapeutics, San Diego, CA, USA., Wu CC; Vividion Therapeutics, San Diego, CA, USA., Hoffman MA; Vividion Therapeutics, San Diego, CA, USA., Snead AN; Vividion Therapeutics, San Diego, CA, USA., Song X; Vividion Therapeutics, San Diego, CA, USA., Glaza T; Vividion Therapeutics, San Diego, CA, USA., Kikuchi S; Vividion Therapeutics, San Diego, CA, USA., Green JC; Vividion Therapeutics, San Diego, CA, USA., Rogness DC; Vividion Therapeutics, San Diego, CA, USA., Lam B; Vividion Therapeutics, San Diego, CA, USA., Rodriguez-Aguirre ME; Vividion Therapeutics, San Diego, CA, USA., Woody DR; Vividion Therapeutics, San Diego, CA, USA., Eissler CL; Vividion Therapeutics, San Diego, CA, USA., Rodiles S; Vividion Therapeutics, San Diego, CA, USA., Negron SM; Vividion Therapeutics, San Diego, CA, USA., Bernard SM; Vividion Therapeutics, San Diego, CA, USA., Tran E; Vividion Therapeutics, San Diego, CA, USA., Pollock J; Vividion Therapeutics, San Diego, CA, USA., Tabatabaei A; Vividion Therapeutics, San Diego, CA, USA., Contreras V; Vividion Therapeutics, San Diego, CA, USA., Williams HN; Vividion Therapeutics, San Diego, CA, USA., Pastuszka MK; Vividion Therapeutics, San Diego, CA, USA., Sigler JJ; Vividion Therapeutics, San Diego, CA, USA., Pettazzoni P; Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Rudolph MG; Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Classen M; Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Brugger D; Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Claiborne C; Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Plancher JM; Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Cuartas I; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain., Seoane J; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain., Burgess LE; Vividion Therapeutics, San Diego, CA, USA., Abraham RT; Vividion Therapeutics, San Diego, CA, USA.; Odyssey Therapeutics, San Diego, CA, USA., Weinstein DS; Vividion Therapeutics, San Diego, CA, USA., Simon GM; Vividion Therapeutics, San Diego, CA, USA., Patricelli MP; Vividion Therapeutics, San Diego, CA, USA. mattp@vividion.com., Kinsella TM; Vividion Therapeutics, San Diego, CA, USA. tkinsella71c@gmail.com.

Publikováno v: Nature [Nature] 2024 Jul; Vol. 631 (8021), pp. E12.

PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models.

Autor: Mitchell LA; Tocagen Inc., San Diego, 92121, CA, USA., Yagiz K; Tocagen Inc., San Diego, 92121, CA, USA., Hofacre A; Tocagen Inc., San Diego, 92121, CA, USA., Viaud S; Tocagen Inc., San Diego, 92121, CA, USA., Munday AW; Tocagen Inc., San Diego, 92121, CA, USA., Espinoza FL; Tocagen Inc., San Diego, 92121, CA, USA., Mendoza D; Tocagen Inc., San Diego, 92121, CA, USA., Rodriguez-Aguirre ME; Tocagen Inc., San Diego, 92121, CA, USA., Bergqvist S; Biofizik, Inc., San Diego, 92121, CA, USA., Haghighi A; Tocagen Inc., San Diego, 92121, CA, USA., Miner MV; Tocagen Inc., San Diego, 92121, CA, USA., Accomando WP; Tocagen Inc., San Diego, 92121, CA, USA., Burrascano C; Tocagen Inc., San Diego, 92121, CA, USA., Gammon D; Tocagen Inc., San Diego, 92121, CA, USA., Gruber HE; Tocagen Inc., San Diego, 92121, CA, USA., Jolly DJ; Tocagen Inc., San Diego, 92121, CA, USA., Lin AH; Tocagen Inc., San Diego, 92121, CA, USA.

Publikováno v: Oncotarget [Oncotarget] 2019 Mar 19; Vol. 10 (23), pp. 2252-2269. Date of Electronic Publication: 2019 Mar 19 (Print Publication: 2019).

Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer.

Autor: Fan, Wen-Xuan, Su, Fei, Zhang, Yan, Zhang, Xiao-Ling, Du, Yun-Yi, Gao, Yang-Jun, Li, Wei-Ling, Hu, Wen-Qing, Zhao, Jun

Publikováno v: Biomarker Research; 8/26/2024, Vol. 12 Issue 1, p1-14, 14p

Therapeutic activity of retroviral replicating vector-mediated gene therapy in combination with anti-PD-1 antibody in a murine pancreatic cancer model.

Autor: Niwa H; Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Sapporo, Hokkaido, Japan., Nakamura T; Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Sapporo, Hokkaido, Japan. torunakamura@med.hokudai.ac.jp., Kushiya H; Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Sapporo, Hokkaido, Japan., Kuraya T; Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Sapporo, Hokkaido, Japan., Inoko K; Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Sapporo, Hokkaido, Japan., Inagaki A; Department of Neurological Surgery, University of California, San Francisco, CA, USA., Suzuki T; Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Sapporo, Hokkaido, Japan., Sasaki K; Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Sapporo, Hokkaido, Japan., Tsuchikawa T; Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Sapporo, Hokkaido, Japan., Hiraoka K; Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Sapporo, Hokkaido, Japan.; Department of Clinical Research, NHO Hakodate National Hospital, Hakodate, Hokkaido, Japan., Shichinohe T; Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Sapporo, Hokkaido, Japan., Hatanaka Y; Center for Development of Advanced Diagnostics (C-DAD), Hokkaido University Hospital, Sapporo, Japan., Jolly DJ; Tocagen Inc., San Diego, CA, USA.; Abintus Bio Inc., San Diego, CA, USA., Kasahara N; Department of Neurological Surgery, University of California, San Francisco, CA, USA. Noriyuki.Kasahara@ucsf.edu.; Department of Radiation Oncology, University of California, San Francisco, CA, USA. Noriyuki.Kasahara@ucsf.edu., Hirano S; Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Sapporo, Hokkaido, Japan.

Publikováno v: Cancer gene therapy [Cancer Gene Ther] 2024 Sep; Vol. 31 (9), pp. 1390-1401. Date of Electronic Publication: 2024 Jul 23.

Viruses as tools in gene therapy, vaccine development, and cancer treatment.

Autor: bin Umair, Musab, Akusa, Fujimura Nao, Kashif, Hadia, Seerat-e-Fatima, Butt, Fatima, Azhar, Marium, Munir, Iqra, Ahmed, Muhammad, Khalil, Wajeeha, Sharyar, Hafiz, Rafique, Shazia, Shahid, Muhammad, Afzal, Samia

Publikováno v: Archives of Virology; Jun2022, Vol. 167 Issue 6, p1387-1404, 18p